![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00170898 |
This study is designed to develop our understanding of the risk-benefit of using lumiracoxib in patients with acute musculoskeletal pain due to uncomplicated soft tissue injury.
Condition | Intervention | Phase |
---|---|---|
Musculoskeletal Pain |
Drug: Lumiracoxib |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | A 7-Day Multicenter Randomized Double-Blind, Double-Dummy Parallel Group Trial to Assess the Safety and Efficacy of 400 mg Lumiracoxib Once Daily Versus 500 mg Naproxen Twice Daily in Patients With Acute Musculoskeletal Pain Due to Uncomplicated Soft Tissue Injury |
Estimated Enrollment: | 419 |
Study Start Date: | November 2004 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria
Exclusion Criteria
Other protocol-defined inclusion/ exclusion criteria may apply.
United Kingdom | |
For site information contact, Novartis Pharmaceuticals UK Limited | |
Frimley, United Kingdom |
Study Director: | Novartis Pharmaceuticals UK Limited Novartis Pharmaceuticals UK Limited | Novartis Pharmaceuticals UK Limited |
Study ID Numbers: | CCOX189AGB02 |
Study First Received: | September 9, 2005 |
Last Updated: | October 12, 2006 |
ClinicalTrials.gov Identifier: | NCT00170898 |
Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Musculoskeletal pain cyclooxygenase-2 inhibitors lumiracoxib naproxen |
Prexige Naproxen Soft Tissue Injuries Pain |
Anti-Inflammatory Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Cyclooxygenase Inhibitors Enzyme Inhibitors Cyclooxygenase 2 Inhibitors Gout Suppressants Pharmacologic Actions |
Analgesics, Non-Narcotic Sensory System Agents Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents |